NOTTINGHAM, UK – January 14, 2013 – Novozymes Biopharma,
part of Novozymes A/S world leader in bioinnovation, today announced
the introduction of a new brand and visual identity for its recombinant
human albumin (rAlbumin) portfolio. As part of the rebrand, Novozymes
will bring both of the company’s rAlbumin products under its well-
established Recombumin® brand. Albucult will be renamed Recombumin
Alpha, while Recombumin will now be known as Recombumin Prime in
order to better synchronize the company’s product offering and create
clarity for customers.
The newly announced changes are purely to the brand and visual
identity of Novozymes rAlbumins. Customers can be reassured that the
products themselves, as well as the product codes, will remain exactly
the same. As part of the rebrand customers will see the changes
reflected on both marketing materials and product labeling.
The molecule in Novozymes’ two rAlbumin products is identical in
respect of amino acid sequence and protein structure. They are both
expressed in Novozymes’ proprietary Saccharomyces host and are
manufactured in compliance with ICH Q7 cGMP guidelines. The products’
physicochemical properties and customer applications are essentially
identical and the name change has been introduced to allow Novozymes
to market these two albumins under a single family name.
Novozymes’ rAlbumins provide a secure supply of batch-to-batch
consistent materials and are supported by a strongly documented safety
package and drug master file. With excellent purity profiles and offering
an established pathway through the regulatory approval process, the
products have earned a strong reputation in the industry for helping
customers to facilitate the safe and successful commercialization of new
products.
“Novozymes is delighted to announce that it is synchronizing the
branding of its rAlbumin products under the Recombumin family name
to enhance the clarity of the company’s product offering, while still
providing customers with the same superior solutions”, says Dermot
Pearson, Marketing Director, Novozymes Biopharma. He continues,
“Since we launched our rAlbumins the portfolio has gone from strength-
to-strength helping Novozymes to become one of the fastest growing
companies in the industry.”
Novozymes’ rAlbumins are compliant with the National Formulary (NF)
rAlbumin human monograph published by the United States
Pharmacopeia (USP) and have been optimized to deliver stable, safe and
regulatory compliant ingredients for the medical device, drug delivery
and formulation markets. Manufactured without animal-derived
materials the products can be used in a wide-range of applications
including stabilization of drugs and vaccines, device coating, advanced
cell therapy products, and in sealants and hemostats.
For further information on Novozymes’ Recombumin Alpha and
Recombumin Prime products, please visit
www.biopharma.novozymes.com
About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad
array of industries, we create tomorrow’s industrial biosolutions, improving our customers'
business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes’ bioinnovations improve
industrial performance and safeguard the world’s resources by offering superior and
sustainable solutions for tomorrow’s ever-changing marketplace. Read more at
www.novozymes.com.
Contact:
Novozymes Biopharma:
Niklas Andersson, Global Communications Manager
NLAN@novozymes.com
Tel. +44 115 955 3355
MEDIA CONTACTS
Europe
René Tronborg
Office: +45 4446 2274
Mobile: +45 3077 2274
retr@novozymes.com
China
Zhu Xiaoqing
Office: +86 106 298
7888+362
Mobile: +86 138 012 40590
xqzh@novozymes.com
US
Paige Donnelly
Office: +1 919 494 3209
Mobile: +1 919 218 4501
pagd@novozymes.com
Brazil
Ana Cecilia Amarante de
Oliveira
Office: +55 41 3641 1096
Mobile: +55 41 9619 7594
aaov@novozymes.com
INVESTOR CONTACTS
US
Thomas Steenbech Bomhoff
Mobile: +1 919 649 2565
tsbm@novozymes.com